• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

    41.64 -0.05 (-0.12%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 11, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 707,157
    Open 41.81
    Bid (Size) 40.01 (100)
    Ask (Size) 51.76 (200)
    Prev. Close 41.69
    Today's Range 41.62 - 42.44
    52wk Range 41.11 - 59.68
    Shares Outstanding 53,145,884
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    1 of Wall Street’s Favorite Stocks with Promising Prospects and 2 Facing Headwinds
    The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
    Via StockStory
    News headline image
    Supernus Pharmaceuticals to Participate in September Investor Conferences
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -15.8%
    -15.8%
    1 Month
    -11.2%
    -11.2%
    3 Month
    -8.6%
    -8.6%
    6 Month
    -17.5%
    -17.5%
    1 Year
    -9.9%
    -9.9%

    More News

    Read More
    News headline image
    3 Out-of-Favor Stocks We’re Skeptical Of
    Via StockStory
    News headline image
    Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    News headline image
    3 Small-Cap Stocks with Open Questions
    Via StockStory
    News headline image
    1 Healthcare Stock with Exciting Potential and 2 We Ignore
    Via StockStory
    Topics Retirement
    News headline image
    Supernus Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript ↗
    Via Benzinga
    Topics Earnings
    News headline image
    3 Russell 2000 Stocks We Approach with Caution
    Via StockStory
    News headline image
    Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
    From Kahn Swick & Foti, LLC
    Via Business Wire
    News headline image
    Why Supernus Pharmaceuticals Stock Topped the Market Today ↗
    Via The Motley Fool
    News headline image
    Halper Sadeh LLC is Investigating Whether SUPN, ITGR, BOW are Obtaining Fair Deals for their Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    News headline image
    SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    News headline image
    Supernus Pharmaceuticals Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    What's going on in today's pre-market session ↗
    Via Chartmill
    News headline image
    Supernus Pharmaceuticals (NASDAQ:SUPN) Surprises With Q2 CY2026 Sales, Stock Jumps 24.9%
    Via StockStory
    News headline image
    Supernus Announces Second Quarter 2026 Financial Results
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
    From Supernus Pharmaceuticals, Inc.; Indivior Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Supernus Pharmaceuticals Earnings: What To Look For From SUPN
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    1 Cash-Producing Stock on Our Buy List and 2 That Underwhelm
    Via StockStory
    News headline image
    1 Growth Stock to Stash and 2 We Turn Down
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Branded Pharmaceuticals Stocks Q1 Teardown: Supernus Pharmaceuticals (NASDAQ:SUPN) Vs The Rest
    Via StockStory
    Topics Artificial Intelligence Intellectual Property
    News headline image
    3 of Wall Street’s Favorite Stocks We Approach with Caution
    Via StockStory

    Frequently Asked Questions

    Is Supernus Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Supernus Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Supernus Pharmaceuticals, Inc. - Common Stock trade on?
    Supernus Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock is SUPN on the Nasdaq Stock Market
    What is the current price of Supernus Pharmaceuticals, Inc. - Common Stock?
    The current price of Supernus Pharmaceuticals, Inc. - Common Stock is 41.64
    When was Supernus Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Supernus Pharmaceuticals, Inc. - Common Stock was at 09/11/26 04:00 PM ET
    What is the market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock is 2.21B
    How many shares of Supernus Pharmaceuticals, Inc. - Common Stock are outstanding?
    Supernus Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.